Postinfectious Irritable Bowel Syndrome and Gelsectan
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Irritable Bowel Syndrome (IBS) is one of the most common conditions diagnosed in
gastroenterology practice. Acute infectious gastroenteritis represents the strongest known
risk factor for IBS development; a condition known as post-infection IBS (PI-IBS). PI-IBS
patients are more likely than sporadic IBS patients to exhibit a diarrhea-predominant
phenotype. The investigators plan to prospectively recruit two groups of patients: patients
with diarrhea-predominant post-infectious IBSand patients with diarrhea predominant classical
IBS (non PI-IBS) who will be used as controls.
Patients included in the study will receive for 28 days a capsule containing Tamarind seed
polysaccharide containing xyloglucan, combined with a pea protein reticulated with grape seed
extractand a prebiotic, the xilooligosaccharide (Gelsectan, Devintec Sagl) twice daily.